A5175: A PHASE IV, PROSPECTIVE, RANDOMIZED, OPEN-LABEL EVALUATION OF THE EFFICAC

A5175：第四阶段、前瞻性、随机、开放标签的功效评价

• 批准号: 7604202
• 负责人: ROY M. GULICK
• 金额: $ 0.16万
• 依托单位: WEILL MEDICAL COLL OF CORNELL UNIV
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-04-01 至 2007-09-16
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7604202
• 关键词: Anti-Retroviral Agents; CD4 Lymphocyte Count; Cells; Computer Retrieval of Information on Scientific Projects Database; Daily; Evaluation; Funding; Grant; HIV-1; Institution; Label; Persons; Pharmaceutical Preparations; Phase; Protease Inhibitor; RNA-Directed DNA Polymerase; Randomized; Research; Research Personnel; Resources; Source; Treatment Protocols; United States National Institutes of Health; prospective

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Hypotheses: Three-drug antiretroviral (ARV) regimens administered once-daily and twice-daily provide similar ARV benefit in resource-limited settings for HIV-1- infected persons with CD4+ cell counts <300 cells/mm3. A three-drug ARV regimen containing a protease inhibitor (PI), administered once-daily, provides similar ARV benefit in resource-limited settings for HIV-1-infected persons with CD4+ cell counts <300 cell/mm3 as compared with a three-drug ARV regimen administered twice daily that contains an non-nucleosis reverse transcriptase (NNRTI).

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目和 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 假设：对于 CD4+ 细胞计数 <300 个细胞/mm3 的 HIV-1 感染者，每天一次和每天两次的三种药物抗逆转录病毒 (ARV) 方案在资源有限的环境中提供类似的 ARV 益处。 包含蛋白酶抑制剂 (PI) 的三药 ARV 方案每天给药一次，在资源有限的环境中为 CD4+ 细胞计数 <300 个细胞/mm3 的 HIV-1 感染者提供了与三药方案相似的 ARV 益处。药物抗逆转录病毒疗法每天给药两次，其中含有非核细胞逆转录酶（NNRTI）。